Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.

@article{Roberts2014OutcomesOC,
  title={Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.},
  author={Kathryn G. Roberts and Deqing Pei and Dario Campana and Debbie Payne-Turner and Yongjin Li and Cheng Cheng and John T. Sandlund and Sima Jeha and John Easton and Jared B. Becksfort and Jinghui Zhang and Elaine Coustan-Smith and Susana C. Raimondi and Wing H Leung and Mary V. Relling and William E. Evans and James R. Downing and Charles G Mullighan and Ching-Hon Pui},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 27},
  pages={3012-20}
}
PURPOSE BCR-ABL1–like acute lymphoblastic leukemia (ALL) is a recently identified B-cell ALL (B-ALL)subtype with poor outcome that exhibits a gene expression profile similar to BCR-ABL1-positive ALL but lacks the BCR-ABL1 fusion protein. We examined the outcome of children with BCR-ABL1–like ALL treated with risk-directed therapy based on minimal residual… CONTINUE READING